Improving quality of life of Parkinson’s disease patients by Quantitative Cognitive Testing

ended

Parkinson’s disease is dominated by motor symptoms such as tremor, bradykinesia and postural instability. However, over 90% of all patients develop cognitive impairment including deterioration of learning, memory and decision making. Current treatments focus on motor symptoms and offer at best moderate improvement of cognitive functions. Alleviating cognitive symptoms could dramatically increase quality of life of patients. Therefore, we propose to apply a behavioral test of fine decision making combined with electroencephalography and electromyography measurements to quantitatively assess complex aspects of cognitive function, including inhibitory control, learning by reinforcement and decision making under conflict. This Quantitative Cognitive Testing (QCT) can be employed to improve Parkinson’s disease therapy based on regular feedback. Moreover, the method can be extended to other domains of neurodegenerative dementias. We foresee that the application of QCT can facilitate the development of telemedicine packages, thus reducing hospital visits and patient-doctor contacts. Under this PoC, we propose to validate equipment we developed de novo, conduct proof of concept experiments, extend IPR protection, and explore commercialization strategies. We believe that QCT can help achieve the best possible cognitive function, which would improve the quality of life of patients and their families. It could also reduce disease-related cost burden on health care systems and society, making it appealing to health providers.